Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 3 of about 3   

Articles published

DVAX 22.70 +0.33 (1.48%)
price chart
Andrew Gengos out, John Walker in as Neuraltus CEO
Andrew Gengos, who led Neuraltus Pharmaceuticals Inc. into a Phase II trial of its experimental treatment for Lou Gehrig's disease, has left the company. Veteran Bay Area biotech executive John Walker, Neuraltus' chairman, took over Aug. 15 as interim ...
3 Vaccine Companies With Upcoming Catalysts
Dynavax Technologies Corporation (NASDAQ:DVAX), a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases.
Related articles »  
FDA Approval of Dynavax's (DVAX) Groundbreaking Hep-B Vacccine Could ...
With a current market value of $800 million and the market for hep-B vaccines at about $1.5 billion, sales of Dynavax's proposed vaccine getting about half the market share by 2018 could double the value of the company. Shares are up about 4 percent ...